Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2011. The report details a specific corporate action regarding share repurchases executed on August 4, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to treasury shares.
- Shares Purchased: 1,700,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,343 pence per share; lowest price paid was 1,306 pence per share.
- Treasury Holdings (Settled): 498,721,816 shares (8.90% of total issued share capital).
- Treasury Holdings (Including Unsettled): 502,996,816 shares (9.85% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,106,474,212 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,700,000 shares for treasury. This action increased the percentage of total voting rights held in treasury from the prior level to 9.85% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The stated intent is to hold the repurchased shares in Treasury. The document notes that the number of shares in issue (excluding treasury) serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (498,721,816 settled) against the company's latest capitalization table.
- Confirm the total voting rights percentage held in Treasury (9.85% including unsettled shares).
- Check the total issued share capital excluding treasury shares (5,106,474,212) for accurate EPS and ownership percentage calculations.
- Review the price range paid (1,306 to 1,343 pence) to assess the cost of capital reduction relative to market prices on August 4, 2011.